Enhancement of anti-tumor immunity and survival prolongation by neoadjuvant 5-FU, oxaliplatin and irinotecan (folfirinox) in pancreatic ductal adenocarcinoma patients. (March 2018) - Cai, L.; Michelakos, T.; Castillo, C.F.; Yamada, T.; Taylor, M.S.; Deshpande, V.; Qadan, M.; Allen, J.; Clark, J.W.; Hong, T.S.; Ryan, D.P.; Wo, J.Y.; et al.